Metabolites of the Nitric Oxide (NO) Pathway Are Altered and Indicative of Reduced NO and Arginine Bioavailability in Patients with Cardiometabolic Diseases Complicated with Chronic Wounds of Lower Extremities: Targeted Metabolomics Approach (LC-MS/MS)

Figure 2

Intermediates in the arginine/NO pathway in chronic wounds: (a) arginine, (b) citrulline, (c) ADMA, (d) SDMA, (e) arginine-to-ADMA ratio (Arg/ADMA), and (f) arginine-to-SDMA ratio (Arg/SDMA). Data are presented as medians with 95% confidence intervals and analyzed using the Kruskal-Wallis test. CM+W: patients with cardiometabolic diseases and chronic wounds; CM: patients with cardiometabolic diseases without chronic wounds; HC: healthy controls. Numbers below the dot plots represent the mean value within a group. Letters above the dot plots indicate groups from which a given group mean differs significantly: A: significantly different from CM+V; B: significantly different from CM; C: significantly different from HC.

(a)

(b)

(c)

(d)

(e)

(f)